How I manage frontline transplant-eligible multiple myeloma in Italy.

Authors :: Montefusco V
Martinelli G
Cerchione C
Source :: Hematology reports [Hematol Rep] 2020 Sep 21; Vol. 12 (Suppl 1), pp. 8954. Date of Electronic Publication: 2020 Sep 21 (Print Publication: 2020).
Publication Year :: 2020
Abstract: The treatment of transplant-eligible multiple myeloma patients in Italy consists in an induction phase based on bortezomib plus thalidomide plus dexamethasone (VTd), followed by a single or tandem autologous stem cell transplantation (ASCT), followed by lenalidomide maintenance. This approach offers an overall response rate of 93% and a CR rate of 58% with acceptable toxicity. Lenalidomide maintenance adds a significant increase in disease control, with a progression free survival after ASCT of 53 months, and an overall survival of 86 months. Second primary malignancies represent the most concerning toxicity of lenalidomide maintenance with a 6.9% incidence. However, the benefit in terms of increased myeloma control largely outweigh this complication. The incorporation of daratumumab in this treatment schema will further improve these clinical results.<br />Competing Interests: Conflict of interest: VM has received honoraria and travel grants from Janssen, Celgene, Bristol-Myers Squibb, Amgen and Takeda.<br /> (©Copyright: the Author(s).)